NCT06592014Enrolling by invitationPhase 1/2
Lithium for Parkinson's: an Extension Trial
Repurposing Lithium as a Disease-modifying Therapy in Parkinson's Disease: an Open-label Extension Trial.
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
This study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week lithium clinical trials.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- First submitted
- 8 Sept 2024
- Start date
- 9 Aug 2024
- Primary completion date
- 1 Oct 2027
- Lead sponsor
- State University of New York at Buffalo
- Diseases
- Parkinson disease
- NCT number
- NCT06592014
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 35
- From 9 Aug 2024 to the primary completion date, 1 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- All PD patients completing STUDY00007253 or STUDY00008239 at the University at Buffalo will be eligible.
- No unstable cardiac, medical, neurologic or psychiatric condition in the opinion of the PI.
- No current use of illicit drugs or current alcohol abuse in the opinion of the PI.
- No history of brain surgery or possible need for brain surgery including deep brain stimulation (DBS) for at least 24 weeks in the opinion of the PI.
- Women with child bearing potential will need a negative pregnancy test and not be nursing an infant at screening. Women with child bearing potential will need to report using barrier method or hormonal contraception.
- Willing and able to sign informed consent and follow study procedures.
Age in the registry: 45 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UBMD Neurology Coordinator of this site? Confirm its status | Williamsville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.